Invivyd Inc. Common Stock Earnings Recaps
Q1 2026
May 15, 2026
Invivyd’s stock plunged 21.1% following its Q1 2026 earnings release, driven primarily by a cautious outlook amid slowing COVID vaccine revenues and concerns over margin pressures, despite ongoing monoclonal antibody revenue growth.
Key takeaways
- Monoclonal antibody revenues continued to grow, offsetting declines in COVID vaccine utilization and associated revenue.
- The company slowed recruitment in its DECLARATION pivotal study to align with seasonal COVID-19 waves, potentially signaling challenges in near-term growth visibility.
- Management highlighted increased government affairs activity but did not provide concrete guidance upgrades, reflecting a measured tone on near-term prospects.
- The neutralization confirmation against Omicron BA.3.2 was acknowledged but seen as less impactful given the variant’s limited clinical threat.
- Early pipeline expansion was noted, but no immediate commercial catalysts were detailed, leaving investor focus on current performance and near-term outlook.
Q3 2025
Nov 6, 2025
Invivyd's Q3 2025 results reflect a pivotal shift towards advancing its COVID prevention efforts, bolstered by significant FDA feedback and a strategic fundraising initiative that provides robust financial support for upcoming clinical programs.
Key takeaways
- Invivyd raised approximately $87 million in capital to fund pivotal studies for its vaccine alternative antibody, VYD2311, positioning the company for key developments ahead.
- The FDA has provided encouraging feedback to develop VYD2311 for broader populations that are underserved by current COVID vaccines, expanding Invivyd’s market opportunity.
- The imminent launch of VYD2311 is supported by anticipated manufacturing capacities and a disciplined approach to operating expenditures.
- Upcoming clinical trials aim to deliver top-line results by mid-2026, with a focus on establishing VYD2311's protection efficacy and safety in comparison to existing mRNA vaccines.